NMN (nicotinamide mononucleotide) – what is it, longevity, and is it worth supplementing after 40?

NMN (nicotinamide beta-mononucleotide) is one of the most discussed supplements of the last decade in the context of longevity and slowing down aging. Research on mice by David Sinclair's group (Harvard) sparked a wave of interest, and the product began to be used by millions of people worldwide – before proper clinical studies on humans were completed. In this article, we discuss what we really know about NMN: mechanisms of action, evidence from human studies up to 2026, dosing, and an honest picture of what we still don't know.

KEY INFORMATION
• NMN is a precursor to NAD+ – a coenzyme crucial for energy metabolism, DNA repair, and mitochondrial function.
• NAD+ levels decrease with age by about 50% between the ages of 20 and 60 – NMN supplementation aims to reverse this trend.
• Human studies (2020–2026): several small RCTs showed an increase in NAD+ in the blood, improved glucose metabolism, and physical performance, but none have yet proven an extension of lifespan.
• Dosage: 250–500 mg/day; doses above 500 mg do not have better clinical support.

What is NAD+ and why does it decrease with age?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all cells, crucial for: energy metabolism (electron transport chain, glycolysis, Krebs cycle – NAD+ accepts electrons as NADH), DNA repair by poly(ADP-ribose) polymerases (PARP – enzymes that repair DNA breaks, consuming large amounts of NAD+), epigenetic regulation by sirtuins (SIRT1-7 – histone and non-histone deacetylases modulating gene expression, involved in aging), mitochondrial function, and autophagy. NAD+ is not taken directly from the outside – it is synthesized in cells from precursors: tryptophan (de novo pathway), niacin (vitamin B3, PP), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN).

Why does NAD+ decrease with age? Increased PARP activity (more DNA damage = more NAD+ consumed), decreased expression of NAD+ synthesis enzymes (NMNAT, NAMPT), increased activity of CD38 – an enzyme that breaks down NAD+ as a signaling molecule. The result: individuals aged 40–50 have NAD+ levels approximately 30–50% lower than 20-year-olds. This reduction correlates (but is not proven to cause) with many features of aging: decreased mitochondrial performance, poorer DNA repair, glucose metabolism disorders.

Our observations: NMN is often described as a "longevity molecule" or "key to reversing aging." This is marketing rhetoric not supported by available human data. NMN raises NAD+ in the blood – that is a fact. Whether the increase in blood NAD+ translates to an increase in NAD+ in specific tissue cells (brain, muscles, heart) – this remains a matter of research. Whether this increase translates to slowing aging in humans over years/decades – this is a hypothesis, not a proven fact. This does not mean that NMN is useless – it means that expectations should be calibrated to "support metabolism and mitochondria," not to "elixir of youth."

Human studies – what do we really know by 2026?

Breakthrough study: Yoshino et al. (Science, 2021) – randomized controlled trial on 25 postmenopausal women with overweight and insulin resistance. Protocol: 250 mg NMN/day for 10 weeks vs placebo. Results: increased NAD+ in skeletal muscles, improved insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, increased expression of genes involved in insulin signaling. Limitation: small study, only postmenopausal women, no assessment of effects on longevity. This is an important and solid study, but the results should not be extrapolated to "NMN for all 40+."

Igarashi et al. (NPJ Aging, 2022) – 250 mg NMN/day for 12 weeks in 12 men aged 65+. Results: increased NAD+ in the blood, improved physical fitness assessment (walking speed, muscle function tests), subjective improvement in fatigue. Limitation: very small sample, no placebo (open study). Huang et al. (GeroScience, 2022) – 300 mg vs 600 mg NMN/day for 60 days vs placebo in healthy adults aged 40–65. Results: dose-dependent increase in NAD+, improved aerobic capacity (VO2max) at 600 mg, no effects on blood pressure or lipids. Important conclusion: the 600 mg dose did not cause serious adverse effects. Suggestion: doses higher than 250 mg may provide better biological effects on physical performance.

Sirtuins – what are they and why do they matter?

Sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylases, discovered by Leonardo Guarente (MIT) and popularized by David Sinclair (Harvard). Each sirtuin has specific functions: SIRT1 and SIRT6 – regulation of gene expression through histone deacetylation, activation of DNA repair, regulation of the insulin-IGF-1 axis; SIRT3 – mitochondrial function, reduction of oxidative stress; SIRT5 – mitochondrial metabolism; SIRT7 – genome stability. A key observation by Sinclair: in mammals, increasing SIRT1 activity through caloric restriction or resveratrol (a polyphenol from red wine) extended lifespan and improved metabolic health. Hypothesis: increasing NAD+ through NMN activates sirtuins and mimics the effects of caloric restriction. This hypothesis is biologically plausible but proven in mice, not in humans in long-term studies. [INTERNAL-LINK: resveratrol → resveratrol-co-to-jest-antyksenobiotyk-i-czy-warto-suplementowac-po-40]

NMN or NR – a comparison of the two main NAD+ precursors

NR (nicotinamide riboside) is a precursor to NAD+ discovered earlier than NMN and has more published clinical studies. Pathway: NR → NMN → NAD+ (NMN is an intermediate product between NR and NAD+). In theory, NMN should be a "more direct" precursor. However, cellular biology complicated this scheme: the study by Grozio et al. (Nature Metabolism, 2019) identified the transporter Slc12a8 as a dedicated NMN transporter to mouse cells, bypassing conversion to NR; however, a similar transporter in humans (SLCO2B1) is not unequivocally confirmed as specific for NMN. Clinical effects: NR – stable increase in NAD+ in the blood (+40–60% after 1–2 weeks, Trammell et al. 2016). NMN – comparable increase, may be faster and more tissue-specific (Yoshino 2021). Head-to-head comparison of NMN vs NR at identical doses is not available in published RCTs on humans until 2026. Practically: if cost is comparable – NMN is a more modern choice; if NR is significantly cheaper – biological effects are likely very similar.

How to dose NMN and when to take it?

Dosage based on available RCTs: 250 mg/day – the most commonly used dose in studies (Yoshino 2021, Igarashi 2022); 300–600 mg/day – effective dose in Huang et al. (2022) for effects on aerobic performance; 1000–2000 mg/day – doses used by David Sinclair and other "longevity biohackers", but without RCTs showing better effects than 500–600 mg. Timing: mornings with a meal – NAD+ is involved in energy metabolism, which is more active during the day. Evening doses may theoretically disrupt the circadian rhythm of NAD+ (NAD+ exhibits a circadian rhythm controlled by SIRT1 and circadian clocks). Effects: increase in NAD+ in the blood appears quickly (1–2 weeks); metabolic effects (glucose, insulin) demonstrated after 10–12 weeks of regular use. [INTERNAL-LINK: mitochondria and energy → koenzym-q10-dlaczego-mitochondria-i-energia-a-nie-tylko-serce-dawkowanie-2026]

Supplement form: capsules or sublingual powder (under the tongue) – the suggestion that the sublingual form may improve bioavailability by bypassing first-pass metabolism in the liver, where some NMN may be converted. No direct RCTs comparing capsules vs sublingual. Stability: NMN is sensitive to moisture and heat – store in a cool, dry place, in a tightly sealed package. Check the expiration date – degraded NMN loses activity.

Safety of NMN – what do we know by 2026?

The safety profile of NMN in available clinical studies is generally good. The study by Irie et al. (Endocrine Journal, 2020) – the first phase of safety studies on healthy Japanese individuals: 500 mg taken at once – well tolerated, no serious adverse effects, increase in NMN and NAD+ in the blood. RCT by Yoshino, Igarashi, Huang – a total of several dozen participants, 10–12 weeks: no serious adverse effects, mild gastric effects at higher doses. Possible side effects: nausea at doses above 500 mg (mild, subsiding when taken with food), headaches (rare), sweating (rare). Unknown: long-term safety (beyond one year) in humans. Note: In 2022, the FDA rejected the application to recognize NMN as a safe food ingredient (GRAS) due to clinical studies treating NMN as a drug (Metro International Biotech LLC). In Poland and the EU, NMN remains available as a dietary supplement.

NMN and mitochondria and physical performance after 40

Mitochondria are a key target for NAD+-dependent interventions. With age, both the number and performance of mitochondria in muscle and nerve cells decline – a phenomenon known as mitochondrial dysfunction. NAD+ is essential for the respiratory chain complexes (particularly complex I, where NADH donates electrons), and low levels of NAD+ directly disrupt ATP production. The study by Airhart et al. (2017, PLOS ONE) on 120 healthy adults evaluated NR (a precursor to NMN): a 60% increase in NAD+ after 8 weeks with no serious adverse effects. Huang et al. (2022, GeroScience) at 300 and 600 mg NMN/day for 60 days showed an improvement in VO2max (maximum oxygen uptake – the gold standard of aerobic performance) in middle-aged adults: at 600 mg, VO2max increased by about 6.6% vs placebo. This is a clinically significant improvement, comparable to the effect of 4–6 weeks of regular aerobic training in a sedentary individual.

For an active person over 40, whose aerobic capacity naturally declines (maximum VO2max decreases by about 1% per year after age 30), supplementation with 300–600 mg of NMN daily in conjunction with regular aerobic training may potentially slow this decline or partially reverse it. Mechanism: increased NAD+ → activation of SIRT3 in muscle mitochondria → improved mitochondrial biogenesis and oxygen utilization. This is a rational hypothesis with preliminary clinical support. Important note: effects in individuals already physically active may be less pronounced than in sedentary individuals, as regular physical activity itself raises NAD+ levels and activates sirtuins. [INTERNAL-LINK: vitamin D and metabolism → witamina-d3-dawkowanie-niedobor-i-dlaczego-sama-d3-nie-wystarczy]

NMN and insulin resistance and glucose metabolism

Insulin resistance – a condition in which muscle and liver cells respond poorly to insulin – affects an estimated 30–40% of adult Poles and is one of the main risk factors for type 2 diabetes, cardiovascular diseases, and obesity. Connection to NAD+: insulin resistance correlates with low levels of NAD+ and SIRT1 dysfunction in skeletal muscles. Yoshino et al. (Science, 2021) demonstrated in the first solid RCT on humans that 250 mg NMN/day for 10 weeks improved insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp (the gold standard for measuring insulin sensitivity) in postmenopausal women with insulin resistance. Gene expression also increased: INSR (insulin receptor), PIK3CA, AKT (insulin signaling pathway in muscles). This suggests that NMN not only "raises NAD+" – it has measurable effects in peripheral tissues. However, 25 participants and one specific population is too few to generalize to everyone. Larger, longer studies in diverse populations are needed.

Who should consider NMN, and who should wait?

Profile of a person justified for NMN: a person over 40 with an active interest in longevity and metabolism, without diseases requiring medication; a person with reduced physical performance, fatigue, and subclinical glucose metabolism disorders; a person willing to use supplementation for 6–12 months and monitor effects (e.g., glucose, insulin, HbA1c levels). Profile without clear benefits (currently): a person under 30 (NAD+ levels are not yet significantly reduced); a person with normal metabolism and no risk factors (potential benefits are marginal); a person expecting dramatic effects in a short time (the effects of NMN are subtle and long-term). NMN is not a drug or a panacea – it is one of the biological support tools for individuals who take an active approach to health and understand the preliminary scientific evidence.

Frequently Asked Questions

Below are answers to the questions most frequently asked in the context of NMN and NAD+.

What is NMN and how does it work?

NMN (nicotinamide mononucleotide) is a precursor to NAD+ – a coenzyme crucial for energy metabolism, DNA repair, and sirtuin functions. NAD+ levels decline with age; NMN supplementation aims to reverse this trend by providing a substrate for NAD+ synthesis.

How to dose NMN?

Based on RCT: 250–500 mg/day in the morning with food. Doses of 300–600 mg have shown effects on aerobic performance (Huang 2022). Doses above 500 mg do not have confirmed better clinical effects than 250–500 mg. Metabolic effects are visible after 10–12 weeks.

Does NMN really work on aging?

In mice: impressive longevity effects. In humans (until 2026): several small RCTs have shown increased NAD+, improved glucose metabolism, and physical performance. No human study has proven life extension or aging inhibition – this remains a hypothesis requiring 10–20 years of research.

Is NMN safe?

In studies lasting 10–12 weeks at doses of 250–1000 mg: well tolerated, no serious adverse effects. Possible: nausea at higher doses. Long-term safety (beyond one year) has not been sufficiently studied. Available in Poland as a dietary supplement.

NMN or NR – which to choose?

Both are precursors to NAD+, both raise NAD+ in the blood. NR – older, more studies, often cheaper. NMN – newer, theoretically a more direct pathway, newer studies with better design. No head-to-head RCT. At comparable prices – NMN; if NR is clearly cheaper – NR is also a good choice.

This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04